Administration of TRPV1 agonist CAP (50 mg/kg s.c.)on day 2 of life resulted in hyperactive schizophrenia-like behavior at weeks 5–7, but increased PPI at weeks 8-1249. Here, TRPV1 is linked to schizophrenia.